Back to top

Analyst Blog

Zacks Equity Research

Novartis' Jakavi Gains EU Approval


 ZacksTrade Now

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at or call 800-767-3771 ext.  9339.

Novartis AG’s (NVS - Snapshot Report) cancer drug Jakavi (INC424/ruxolitinib), a novel JAK1/JAK2 inhibitor, recently received approval from the European Commission for the treatment of myelofibrosis (MF), a life-threatening blood cancer.

The approval was based on encouraging data from the COMFORT (COntrolled MyeloFibrosis Study with ORal JAK Inhibitor Therapy) program, which showed treatment with Jakavi reduced spleen size and manifestations caused by MF. The COMFORT program consisted of two phase III studies – COMFORT I and COMFORT II.

The first pivotal study, COMFORT-I, showed that 41.9% of patients treated with Jakavi achieved at least 35% or 50% reduction in spleen size at 24 weeks in comparison to only 0.7% of patients in the placebo arm.

In the second study, COMFORT-II, treatment with Jakavi resulted in a 35% or more decrease in spleen size in 28% of patients at 48 weeks versus 0% of patients under the best available therapy (BAT) group.

The European approval did not come as a surprise, as Jakavi had earlier received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for the treatment of MF.

Novartis has licensed Jakavi from Incyte Corporation (INCY - Analyst Report) for the development and potential commercialization outside the US. Incyte received approval from the US Food and Drug Administration (FDA) for Jakavi in November 2011.

Jakavi is also being investigated in phase III trials for the treatment of polycythemia vera.   

Our Take

We view Jakavi’s approval for the treatment of myelofibrosis as a major positive for Novartis as this is the first approved medication for MF of the company in the EU.

Currently, we have a Neutral recommendation on Novartis. The company carries a Zacks #3 Rank (Hold rating) in the short run.

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
LAKE SHORE G LSG 0.77 +6.05%
QUESTCOR PHA QCOR 80.07 +2.47%
VIPSHOP HOLD VIPS 156.35 +1.82%
ENLINK MIDST ENLC 36.29 +1.60%
BNC BANCORP BNCN 17.33 +1.58%